Ultra-sensitive test for cancers & HIV developed by Stanford chemists

Photo by Tom Mallinson

Photo by Tom Mallinson

Stanford chemists have now developed a highly sensitive and specific tool to screen cancer and HIV — 1000 times more sensitive than current clinical tests. More precise screening could allow for much earlier detection and treatment, as well as help avoid false positive results and their resulting unnecessary procedures and stress.

Developed in the lab of chemist Carolyn Bertozzi, PhD, this new ultrasensitive screening technique has already been tested as a biomarker for thyroid cancer in clinical trials. The study results were recently reported in ACS Central Science.

Many standard clinical blood tests are based on immunoassays, which use highly specific antibodies to detect specific molecules known to be associated with the target disease. Bertozzi’s new screening test adds the power of DNA detection to this standard procedure. Rather than marking, or “flagging”, disease-related antibodies using customary chemical compounds, the team flagged the antibodies using DNA.

A recent Stanford news release explains:

The researchers tested their technique, with its signature DNA flag, against four commercially available, FDA-approved tests for a biomarker for thyroid cancer. It outperformed the sensitivity of all of them, by at least 800 times, and as much as 10,000 times. By detecting the biomarkers of disease at lower concentrations, physicians could theoretically catch diseases far earlier in their progression.

Bertozzi is currently testing their ultrasensitive screening method in clinical trials for other diseases, including HIV. If its effectiveness is proven, the researchers expect it to be readily adopted in clinics. Cheng-ting “Jason” Tsai, co-author and graduate student in Bertozzi’s group, said in the news release:

Many of our collaborators are excited that the test can be readily deployed in their lab. In contrast to many new diagnostic techniques, this test is performed on pre-existing machines that most clinical labs are already familiar with.

This is a reposting of my Scope blog story, courtesy of Stanford School of Medicine.

Advertisements
Explore posts in the same categories: Health

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s


%d bloggers like this: